The HER2-directed antibody-drug conjugate DHES0815A in advanced and/or metastatic breast cancer: Preclinical characterization and phase 1 trial results Journal Article
| Authors: | Lewis, G. D.; Li, G.; Guo, J.; Yu, S. F.; Fields, C. T.; Lee, G.; Zhang, D.; Dragovich, P. S.; Pillow, T.; Wei, B.; Sadowsky, J.; Leipold, D.; Wilson, T.; Kamath, A.; Mamounas, M.; Violet Lee, M.; Saad, O.; Choeurng, V.; Ungewickell, A.; Monemi, S.; Crocker, L.; Kalinsky, K.; Modi, S.; Jung, K. H.; Hamilton, E.; LoRusso, P.; Krop, I.; Schutten, M. M.; Commerford, R.; Sliwkowski, M. X.; Cho, E. |
| Article Title: | The HER2-directed antibody-drug conjugate DHES0815A in advanced and/or metastatic breast cancer: Preclinical characterization and phase 1 trial results |
| Abstract: | Approved antibody-drug conjugates (ADCs) for HER2-positive breast cancer include trastuzumab emtansine and trastuzumab deruxtecan. To develop a differentiated HER2 ADC, we chose an antibody that does not compete with trastuzumab or pertuzumab for binding, conjugated to a reduced potency PBD (pyrrolobenzodiazepine) dimer payload. PBDs are potent cytotoxic agents that alkylate and cross-link DNA. In our study, the PBD dimer is modified to alkylate, but not cross-link DNA. This HER2 ADC, DHES0815A, demonstrates in vivo efficacy in models of HER2-positive and HER2-low cancers and is well-tolerated in cynomolgus monkey safety studies. Mechanisms of action include induction of DNA damage and apoptosis, activity in non-dividing cells, and bystander activity. A dose-escalation study (ClinicalTrials.gov: NCT03451162) in patients with HER2-positive metastatic breast cancer, with the primary objective of evaluating the safety and tolerability of DHES0815A and secondary objectives of characterizing the pharmacokinetics, objective response rate, duration of response, and formation of anti-DHES0815A antibodies, is reported herein. Despite early signs of anti-tumor activity, patients at higher doses develop persistent, non-resolvable dermal, ocular, and pulmonary toxicities, which led to early termination of the phase 1 trial. © 2024, The Author(s). |
| Keywords: | genetics; clinical trial; antineoplastic agents; antineoplastic agent; animal; metabolism; animals; gene expression; epidermal growth factor receptor 2; breast neoplasms; monoclonal antibody; dna; breast tumor; benzodiazepine derivative; receptor, erbb-2; phase 1 clinical trial; tumor; trastuzumab; antibody; cell; macaca fascicularis; antibody conjugate; immunoconjugates; benzodiazepines; antibodies, monoclonal, humanized; cancer; humans; human; female; dhes0815a |
| Journal Title: | Nature Communications |
| Volume: | 15 |
| ISSN: | 2041-1723 |
| Publisher: | Nature Publishing Group |
| Date Published: | 2024-01-11 |
| Start Page: | 466 |
| Language: | English |
| DOI: | 10.1038/s41467-023-44533-z |
| PUBMED: | 38212321 |
| PROVIDER: | scopus |
| PMCID: | PMC10784567 |
| DOI/URL: | |
| Notes: | Article -- Source: Scopus |
